May 13, 2020
The Patent Trial and Appeal Board will review whether claims of a Merck patent covering the blockbuster diabetes drugs Januvia and Janumet are invalid, shooting down a variety of arguments from the drugmaker that the board should use its discretion to deny Mylan's petition.